Show simple item record

dc.contributor.authorBadrick, E
dc.contributor.authorRenehan, Andrew G
dc.date.accessioned2014-10-08T09:57:34Z
dc.date.available2014-10-08T09:57:34Z
dc.date.issued2014-08
dc.identifier.citationDiabetes and cancer: 5 years into the recent controversy. 2014, 50 (12):2119-25 Eur J Canceren
dc.identifier.issn1879-0852
dc.identifier.pmid24930060
dc.identifier.doi10.1016/j.ejca.2014.04.032
dc.identifier.urihttp://hdl.handle.net/10541/332310
dc.description.abstractDiabetes and cancer are common chronic disorders. The literature has long recognised that type 2 diabetes (T2D) is associated with an increased incident risk of several cancer types, independent of the mutual risk factor, obesity. However, in June 2009, four papers were published simultaneously in Diabetologia, the official journal of the European Association for the Study of Diabetes, raising questions of a link between diabetes therapies, notably the long-acting insulin analogue, glargine, and increased cancer risk. These papers awakened an unprecedented debate in the diabetes community, drawing in cancer experts and bringing together representatives from these two large, traditionally non-intersecting, biomedical communities. This Current Perspective summarises the events that followed the 'breaking news' from summer 2009: the pitfalls encountered; the increased mutual understanding between diabetes and cancer researchers; and the direction of current research. Much of the debate on the clinical impact of this controversy has been played out in the diabetes literature: here, we update the oncology readership.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshHumans
dc.subject.meshHypoglycemic Agents
dc.subject.meshInsulin
dc.subject.meshMetformin
dc.subject.meshNeoplasms
dc.subject.meshRisk Factors
dc.titleDiabetes and cancer: 5 years into the recent controversy.en
dc.typeArticleen
dc.contributor.departmentInstitute of Population Health, University of Manchester, Manchester, UK.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractDiabetes and cancer are common chronic disorders. The literature has long recognised that type 2 diabetes (T2D) is associated with an increased incident risk of several cancer types, independent of the mutual risk factor, obesity. However, in June 2009, four papers were published simultaneously in Diabetologia, the official journal of the European Association for the Study of Diabetes, raising questions of a link between diabetes therapies, notably the long-acting insulin analogue, glargine, and increased cancer risk. These papers awakened an unprecedented debate in the diabetes community, drawing in cancer experts and bringing together representatives from these two large, traditionally non-intersecting, biomedical communities. This Current Perspective summarises the events that followed the 'breaking news' from summer 2009: the pitfalls encountered; the increased mutual understanding between diabetes and cancer researchers; and the direction of current research. Much of the debate on the clinical impact of this controversy has been played out in the diabetes literature: here, we update the oncology readership.


Files in this item

This item appears in the following Collection(s)

Show simple item record